These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 19685457)

  • 21. [Patent rights and the free research. The boundary between basic research and private sector is not longer razor-sharp].
    Westerlund L
    Lakartidningen; 2005 Sep 26-Oct 2; 102(39):2737. PubMed ID: 16245544
    [No Abstract]   [Full Text] [Related]  

  • 22. Private company profiles.
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE23-8. PubMed ID: 12874973
    [No Abstract]   [Full Text] [Related]  

  • 23. What's fueling the biotech engine?
    Aggarwal S
    Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
    [No Abstract]   [Full Text] [Related]  

  • 24. Sunbaked biotechnology in Australia.
    Littlejohn T
    Nat Biotechnol; 2002 Sep; 20(9):873-7. PubMed ID: 12205502
    [No Abstract]   [Full Text] [Related]  

  • 25. The changing norms of the life sciences.
    Shorett P; Rabinow P; Billings PR
    Nat Biotechnol; 2003 Feb; 21(2):123-5. PubMed ID: 12560827
    [No Abstract]   [Full Text] [Related]  

  • 26. The Human Genome Project: a public good.
    Hudson K
    Health Matrix Clevel; 2002; 12(2):367-75. PubMed ID: 12430360
    [No Abstract]   [Full Text] [Related]  

  • 27. Biotech weathers 2Q12 slump.
    Yang W
    Nat Biotechnol; 2012 Aug; 30(8):738. PubMed ID: 22871704
    [No Abstract]   [Full Text] [Related]  

  • 28. Rainbow biotech--South Africa's emerging sector.
    Louët S
    Nat Biotechnol; 2006 Nov; 24(11):1313-6. PubMed ID: 17093464
    [No Abstract]   [Full Text] [Related]  

  • 29. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shift toward early-stage deals favors biotechs.
    Lawrence S
    Nat Biotechnol; 2006 Jan; 24(1):6. PubMed ID: 16404377
    [No Abstract]   [Full Text] [Related]  

  • 31. Public biotech 2006 - the numbers.
    Lähteenmäki R; Lawrence S
    Nat Biotechnol; 2007 Jul; 25(7):729-37. PubMed ID: 17621294
    [No Abstract]   [Full Text] [Related]  

  • 32. When times get tough.
    Jong S
    Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
    [No Abstract]   [Full Text] [Related]  

  • 33. Strategic rethink for German biotechnology.
    Fernandes M; Miska D
    Nat Biotechnol; 2002 Oct; 20(10):970-1. PubMed ID: 12355106
    [No Abstract]   [Full Text] [Related]  

  • 34. BIO 2006 Annual International Convention. Innovations in biotech in China and Italy.
    Tear S; Zarkowska T
    IDrugs; 2006 Jun; 9(6):386-9. PubMed ID: 16752303
    [No Abstract]   [Full Text] [Related]  

  • 35. Human genomes, public and private.
    Nature; 2001 Feb; 409(6822):745. PubMed ID: 11236960
    [No Abstract]   [Full Text] [Related]  

  • 36. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. India's health biotech sector at a crossroads.
    Frew SE; Rezaie R; Sammut SM; Ray M; Daar AS; Singer PA
    Nat Biotechnol; 2007 Apr; 25(4):403-17. PubMed ID: 17420744
    [No Abstract]   [Full Text] [Related]  

  • 38. Trends in biopharmaceutical IPOS: 1996-2005.
    Williams DR; Young CC
    J Health Care Finance; 2006; 33(2):39-54. PubMed ID: 19175239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biotech round the world: focus on Canada.
    Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
    [No Abstract]   [Full Text] [Related]  

  • 40. A lifeline for the biotech sector.
    Kessel M
    Nat Biotechnol; 2009 Feb; 27(2):123-4. PubMed ID: 19204686
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.